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Abstract
For many years, clonidine, an a2-adrenergic receptor (a2-AR) agonist, has been widely used as an
analgesic adjuvant in perioperative conditions and pain therapy. Dexmedetomidine (DMET) is
currently the most potent a2-AR agonist available and was first approved as a sedative agent for use
in the intensive care unit. However, DMET has recently been investigated for its analgesic effects and
has the potential to become an alternative to clonidine.
Introduction and context
Clonidine, an a2-adrenergic receptor (a2-AR) agonist,
has been widely used and investigated as an analgesic
adjuvant for anesthesia and pain therapy. Dexmedeto-
midine (DMET) belongs to the same family but presents
with a different, more favorable pharmacokinetic profile
(Table 1). DMET was first introduced into clinical
practice as a short-term intravenous sedative in the
intensive care unit. Because the drug also demonstrates
analgesic properties related to a2-AR binding (DMET is
8–10-fold more selective for a2-AR than clonidine),
several studies have investigated its use as a systemic
analgesic adjuvant, mostly in the acute perioperative
setting [1]. More recently, DMET has been investigated as
an adjunct to local anesthetics in locoregional anesthesia
and analgesia. However, neurotoxicity studies have not
yet been performed [2] and the benefit of using DMET
over clonidine has not yet been thoroughly assessed.
Nevertheless, recent experimental studies seem to show
that a1-AR activity counterbalances a2-AR-induced
analgesia and, therefore, greater a2-AR selectivity may
enhance the therapeutic window of a2-AR in the
treatment of pain [3]. Furthermore, DMET demonstrates
a synergistic analgesic effect with clonidine at the spinal
level by a mechanism involving their different affinities
for the three a2-AR subtypes. Neither clonidine or DMET
is totally selective for any one of the a2-AR subtypes
but DMET (besides demonstrating a2A-AR binding
properties) seems to have higher a2C-AR affinity than
clonidine [4].
Recent advances
Analgesic effects following systemic administration
a2-AR agonists and opioids act by different mechanisms
and thus their combination produces a synergistic
analgesic effect without increasing the respiratory depres-
sion that is often associated with opioid use. Further-
more, the opioid-sparing effect is generally associated
with a reduction in adverse effects such as nausea and
vomiting. Therefore, a2-AR agonists have been found to
be particularly useful in perioperative conditions. Recent
studies, not surprisingly, show that intraoperative DMET
(bolus dose of 0.5–1 µg/kg, with or without continuous
infusion of 0.5–2 µg/kg per hour) causes a significant
reduction in the need for both intraoperative and
postoperative analgesics in adults [5] and in children
[6].Eveniftheeliminationhalf-lifeofDMETisshort(i.e.,
2–3 hours), the analgesic-sparing effect observed after a
preoperative or an intraoperative administration usually
lasts up to 24 hours, with the anxiolytic, sedative, and
thymoanaleptic properties implicated as being partly
responsible for this effect [6,7]. Self-administration of
DMET by adding to intravenous patient-controlled anal-
gesia morphine (5 µg DMET per 1 mg morphine dose)
improves postoperative analgesia and decreases post-
operative morphine consumption by 30%, as well as
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without additional sedation [8].
Besides the analgesic effect of a2-AR agonists being
independent of the opioid system, the block of
sympathetic over-activity is another benefit of using
these agents for some patients. For example, periopera-
tive management in patients chronically taking opioids
(i.e., opioid addicts and chronic pain patients) is a
challenge because of their higher pain levels, opioid
tolerance, and risk of opioid withdrawal. Although
poorly explored, DMET may have special value in these
patients by helping to control pain and to alleviate
opioid withdrawal symptoms [9].
Even at high doses, a2-AR agonists combine analgesic,
sedative, and anxiolytic properties with preservation of
respiratory function. Although typically-used sedative
drugs (e.g., propofol), short-acting opioids, ketamine,
and midazolam may provide successful sedation, they
can also induce harmful respiratory depression in high-
risk patients and unsuitable paradoxical effects with
agitation in elderly patients. DMET, like other a2-AR
agonists, does not affect respiratory function. Moreover,
DMET seems to possess neuroprotective effects and
attenuates neurocognitive impairment (mainly delirium
and agitation) following anesthesia [10]. In children
undergoing tonsillectomy, the use of an intraoperative
infusion of DMET reduced the frequence of severe
emergence agitation in comparison with an intraopera-
tive infusion of fentanyl. [11]. In the intensive care unit,
the choice of DMET infusion for sedation and analgesia
has a favourable effect on the prevalence and the dura-
tion of delirium and confusion associated with the use of
midazolam or morphine [12,13]. Therefore, systemic
a2-AR agonists may be used as a perioperative supple-
ment to improve locoregional analgesia, and the
pharmacokinetic profile of DMET makes its use easier
than clonidine for that indication. Additionally, pre-
and intraoperative DMET prolongs the duration of the
sensory block of local anesthetics during spinal anesthe-
sia [14] and peripheral nerve block [15]. It is worth
noting that DMET premedication can be provided by
different noninvasive routes, such as buccal and intra-
nasal routes, with a very good bioavailability [16].
Postoperatively, intravenous DMET infusion as an
adjunct to epidural analgesia allows for better pain
control and reduces epidural analgesic consumption
after major surgery [17].
Finally, besides the perioperative administration, it is
interesting to mention the recent (although anecdotal)
report of DMET use in obstetric analgesia. The report
asserts that, because of its high lipophilicity, DMET is
retained in placental tissue and passes less readily than
clonidine into the fetal circulation and thereby is less
susceptible to cause harmful fetal bradycardia. Contin-
uous intravenous DMET infusion has been successfully
used as an adjunct to unsatisfactory analgesia by systemic
opioids in laboring parturients who could not benefit
from epidural analgesia [18,19]. Like clonidine, DMET
demonstrates an antinociceptive effect in visceral pain
conditions [20]. Furthermore, the drug also possesses
attractive properties such as maternal hemodynamic
stability, anxiolysis, and stimulation of uterine
contractions.
Analgesic effects when used in locoregional analgesia
Because the analgesic effect of a2-AR agonists is mostly
mediated at spinal level, neuraxial administration is the
route of choice for DMET. Moreover, its high lipophili-
city allows for rapid absorption into the cerebrospinal
fluid and binding to the spinal cord a2-AR.
A few clinical studies have examined the epidural admini-
stration of DMET (usual dose 1–2 µg/kg) in thoracic
and upper abdominal surgery. Unsurprisingly, epidural
DMET potentiates neuraxial local anesthetics, decreases
intraoperative anesthetic requirements, and improves
postoperative analgesia hence reducing pulmonary com-
plications associated with thoracotomy [21]. However,
according to studies performed to date, DMET does not
seem to offer any significant advantage over clonidine in
this respect; DMET produces a similar prolongation in the
durationofthemotorandsensoryblocksinducedbylocal
anesthetics, regardless of the neuraxial route of
Table 1. Major differences in the pharmacology of clonidine and dexmedetomidine
Clonidine Dexmedetomidine*
Developed in the 1960s Developed in the 1980s
Clinical practice: originally prescribed as a antihypertensive then as an
analgesic in chronic pain (1983)
Clinical practice: tested in volunteers (1991) then used as a sedative in
ICU (1999)
Ratio a2:a1 receptor binding is 200:1 Ratio a2:a1 receptor binding is 1600:1
Octanol/buffer partition coefficient: 0.8 Octanol/buffer partition coefficient: 2.8 More lipophilic (3.5-fold) than
clonidine
Plasmatic half-life T½: 9–12 hours Plasmatic half-life T½: 2–2.5 hours
Protein binding: 50% Protein binding: 94%
*Detomidine, the racemic mixture, is widely used in veterinary medicine; dexmedetomidine is the active isomer of medetomidine. ICU, intensive care unit.
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[24]). Incidence and magnitude of side effects like
sedation and a decrease in systolic blood pressure (25–
30%) following sympathetic block also do not differ. The
lack of advantage resulting from DMET neuraxial use over
clonidine should be taken into account seeing as regular
neurotoxicity screening has not been performed for
DMET. Although the drug has neuroprotective effects,
demyelination in the white matter was observed after
epidural administration of DMET in rabbits [25]. Conse-
quently, advanced pathologic investigations are required
before using DMET by neuraxial route.
Clonidine is currently used as an analgesic adjuvant in
peripheral nerve blocks. Direct inhibitory effects of a2-AR
agonists on the conduction of Ad and C sensory fibers –
inhibitionofIh(hyperpolarization-activated)currentsand
(perhaps) inhibition of tetrodotoxin-resistant Na
+ chan-
nels – accounts for the potentiation of the intensity and
duration of perineural local anesthetics. Experimental
studies show a DMET dose-dependent increase in the
durationofthe sensory block induced bylong-acting local
anesthetics such as bupivacaine and ropivacaine [26,27].
A first prospective study in pediatric patients undergoing
cleft palate repair and receiving greater palatine nerve
block with bupivacaine also demonstrated a 50% increase
in the duration of postoperative analgesia [28]. Once
again, although the experimental studies did not find
neurotoxicity associated with perineural DMET injection,
and have even found less perineural inflammation in the
local anesthetic–DMET groups, caution remains before
widespread clinical use [2]. Finally, peripheral analgesic
effects of DMET that potentiate local anesthetics are
mediated by a2A-AR binding [29]. Similar to the
observations made with clonidine, addition of DMET to
lidocaineforintravenousregionalanesthesiaimprovesthe
quality of intraoperative anesthesia and intra-articular
administration of DMET decreases the need for post-
operative analgesics after arthroscopic knee surgery [30].
Implications for clinical practice
Current perioperative applications for DMET rely on off-
label uses of the drug. Systemic administration (pre-,
intra- and postoperative) is associated with a useful
potentiation of both systemic analgesics, particularly
opioids, and local anesthetic sensory block in neuraxial
and perineural routes. Furthermore, at moderate doses
(bolus dose of <1 µg/kg; continuous infusion <2 µg/kg
per hour), systemic DMET does not seem to induce
unwanted hemodynamic side effects (e.g., hypotension
and bradycardia). Consequently, systemic use as a
supplement to general anesthesia and locoregional
techniques seems the best and the safest indication for
DMET use. However, neuraxial and perineural routes
cannot be recommended before further neurotoxicity
testing. In comparison with clonidine, currently, only the
systemic route seems to show an advantage for DMET in
accordance with the pharmacokinetic profile of the drug,
while the neuraxial route does not seem to offer any
advantage and the perineural route has not been
assessed. Finally, potential applications for DMET out-
side of a perioperative context (i.e., in chronic pain
therapy) certainly deserve further study.
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